JP2023536883A5 - - Google Patents

Info

Publication number
JP2023536883A5
JP2023536883A5 JP2023507428A JP2023507428A JP2023536883A5 JP 2023536883 A5 JP2023536883 A5 JP 2023536883A5 JP 2023507428 A JP2023507428 A JP 2023507428A JP 2023507428 A JP2023507428 A JP 2023507428A JP 2023536883 A5 JP2023536883 A5 JP 2023536883A5
Authority
JP
Japan
Prior art keywords
approximately
concentration
aav particles
pharmaceutical composition
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044955 external-priority patent/WO2022032104A1/en
Publication of JP2023536883A publication Critical patent/JP2023536883A/ja
Publication of JP2023536883A5 publication Critical patent/JP2023536883A5/ja
Pending legal-status Critical Current

Links

JP2023507428A 2020-08-07 2021-08-06 高度に精製されたウイルス粒子のための製剤 Pending JP2023536883A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063128P 2020-08-07 2020-08-07
US202063063108P 2020-08-07 2020-08-07
US63/063,128 2020-08-07
US63/063,108 2020-08-07
PCT/US2021/044955 WO2022032104A1 (en) 2020-08-07 2021-08-06 Formulations for highly purified viral particles

Publications (2)

Publication Number Publication Date
JP2023536883A JP2023536883A (ja) 2023-08-30
JP2023536883A5 true JP2023536883A5 (cg-RX-API-DMAC7.html) 2024-08-14

Family

ID=80114720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507428A Pending JP2023536883A (ja) 2020-08-07 2021-08-06 高度に精製されたウイルス粒子のための製剤

Country Status (10)

Country Link
US (2) US20220040305A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192437A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023536883A (cg-RX-API-DMAC7.html)
KR (1) KR20230049670A (cg-RX-API-DMAC7.html)
CN (1) CN116323925A (cg-RX-API-DMAC7.html)
AU (1) AU2021320395A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190596A1 (cg-RX-API-DMAC7.html)
IL (1) IL300323A (cg-RX-API-DMAC7.html)
MX (1) MX2023001411A (cg-RX-API-DMAC7.html)
WO (1) WO2022032104A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096867A (zh) * 2020-06-02 2023-05-09 詹森生物科技公司 用于病毒纯化的材料和方法
US20230090654A1 (en) * 2021-08-24 2023-03-23 Homology Medicines, Inc. Adeno-associated virus formulations
CN120603600A (zh) * 2023-01-19 2025-09-05 优尼科生物制药有限公司 基因递送媒介物的药物配制品
KR20260019635A (ko) * 2023-06-09 2026-02-10 사르토리우스 비아이에이 세퍼레이션스 디.오.오. 완전 충전 아데노 관련 바이러스 (aav) 캡시드의 향상된 분리 방법
WO2025045082A1 (zh) * 2023-09-01 2025-03-06 康霖生物科技(杭州)有限公司 一种缓冲系统及其相应液体制剂及其用途
CN122580434A (zh) * 2023-11-30 2026-08-14 优尼科生物制药有限公司 用于病毒药物产品的配制品
CN118957152B (zh) * 2024-08-30 2025-11-25 浙江恒驭生物科技有限公司 一种腺相关病毒载体基因组滴度检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048005A1 (en) * 1997-04-24 1998-10-29 University Of Washington Targeted gene modification by parvoviral vectors
US6156303A (en) * 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP2420247A1 (en) * 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
ES2932278T3 (es) * 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
KR102799163B1 (ko) * 2015-09-17 2025-04-21 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Galgt2 유전자 치료 방법 및 물질
US11015174B2 (en) * 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
TW201837170A (zh) * 2017-02-28 2018-10-16 賓州大學委員會 新穎aav媒介的流感疫苗
IL319002A (en) * 2018-06-14 2025-04-01 Regenxbio Inc Anion exchange chromatography for recombinant AAV production
WO2020023612A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
JP7630443B2 (ja) * 2019-04-19 2025-02-17 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法

Similar Documents

Publication Publication Date Title
JP7531654B2 (ja) アデノ随伴ウイルス精製方法
US12351832B2 (en) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
JP7539420B2 (ja) アデノ随伴ウイルスの精製方法
US20210324343A1 (en) Recombinant adeno-associated virus particle purification comprising an affinity purification step
JP5268890B2 (ja) Aavの規模適応性の製造方法
JP2021087431A5 (cg-RX-API-DMAC7.html)
JP2021530548A5 (cg-RX-API-DMAC7.html)
JP2022516283A5 (cg-RX-API-DMAC7.html)
JP2022549380A5 (cg-RX-API-DMAC7.html)
JP2022547197A5 (cg-RX-API-DMAC7.html)
CN113993552A (zh) 腺相关病毒载体制剂和方法
JP2022533448A5 (cg-RX-API-DMAC7.html)
RU2785661C2 (ru) Способы очистки аденоассоциированных вирусов
CA2975569C (en) Recombinant adeno-associated virus particle purification comprising an affinity purification step
HK1227436A (en) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
HK1227436A1 (en) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography